Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength

Merck beat third-quarter estimates, reporting adjusted EPS of $2.49 versus $2.08 expected and revenue of $18.09B versus $17.31B, up 5% year over year. It raised adjusted EPS guidance to $2.77–$2.82 from $2.66–$2.76, including a $400M licensing-related charge, and narrowed the low end of 2026 revenue guidance to $66.8B from $66.3B. Keytruda sales were $8.60B, including $830M from injectable Qlex, while Winrevair and Gardasil also beat estimates; animal health sales were slightly below estimates.

Analysis

The key question is not whether Qlex is growing, but how much of that growth is incremental versus a switch from intravenous Keytruda—and whether its formulation, reimbursement and patent protections actually delay erosion after 2028. Treat Qlex’s sales as a transition metric until Merck discloses conversion, net pricing and persistence data. If the switch preserves treatment share and economics, it can soften the cliff; it does not by itself remove it.

The earnings beat improves near-term confidence, but the quality of the signal is mixed: adjusted EPS excludes acquisition and restructuring costs, while the outlook incorporates a one-time licensing charge. Winrevair’s growth broadens the pipeline beyond Keytruda, though one strong quarter does not establish its longer-term commercial ceiling. Gardasil’s rebound is less bankable until demand proves durable across geographies and inventory normalization is clearer. Animal health slightly below estimates is a modest offset, not the central thesis.

Over the next 1–3 months, watch Qlex uptake and management’s evidence of net growth in total Keytruda economics. Over 6–18 months, the decisive issue is whether newer products and acquired assets can replace earnings exposed to the 2028 patent cycle. The contrarian risk is that investors extrapolate Qlex’s launch curve while underestimating cannibalization and the eventual price/mix impact of competition.

Key Decisions for Investors

• Prefer a measured long MRK on post-results weakness rather than chasing the initial reaction; the guidance reset and product breadth support the near-term case, but the patent-cliff offset is not yet proven. No price target without valuation and current-price data.
• Treat Qlex as a watch item, not yet as a standalone replacement for Keytruda: verify switching rates, total Keytruda sales split, net pricing/reimbursement, and the relevant exclusivity protections before underwriting durable post-2028 economics.
• Monitor the next 1–3 months for Qlex growth translating into stable or rising total Keytruda revenue, and for continued Winrevair momentum. A slowdown in either, or a cut to the 2026 revenue range, would weaken the constructive thesis.
• Falsification: broad deterioration in total Keytruda sales despite Qlex growth, evidence that Qlex is mainly cannibalizing the IV formulation without preserving economics, or renewed Gardasil weakness after inventory effects fade.